OTCM
YIHCF
Market cap643mUSD
Sep 15, Last price
0.55USD
Name
Yichang Hec Changjiang Pharmactcl Co Ltd
Chart & performance
P/E
8.87
P/S
1.15
EPS
0.41
Vol. 1Y
—
Shs. 5Y
-2.71%
Rev. 5Y
-9.76%
Div Yld LY
—
Div Yld TTM
—
Revenues
3.72b
-40.84%
Net income
483m
-75.78%
CFO
89m
-94.66%
Dividend
Aug 04, 20250.1911 USD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. is a Chinese pharmaceutical enterprise primarily engaged in the development, manufacturing, and distribution of medicinal products. Operating within the People's Republic of China, its therapeutic expertise spans antiviral treatments, solutions for endocrine and metabolic disorders, and cardiovascular health. In addition to finished pharmaceuticals, the company produces and markets active pharmaceutical ingredients (APIs) and dedicates resources to the research and development of medical devices, novel drugs, and biotechnology. It also extends its services to include medical consulting. The company's products reach hospitals and other healthcare institutions through an established network of distributors. YiChang HEC ChangJiang Pharmaceutical has forged strategic alliances with several prominent entities, including a cooperation framework agreement with Alibaba Health Technology (China) Limited for specialized influenza projects. Other key partners encompass Jointown Pharmaceutical Group Co., Ltd., Guangdong Yihao Pharmaceutical Co., Ltd., Shenzhen HEC Industrial Development Co., Ltd., and China National Accord Medicines Corporation Ltd. Founded in Yichang, China, in 2001, the company was originally known as Yichang Changjiang Pharmaceutical Company Limited before its rebranding to YiChang HEC ChangJiang Pharmaceutical Co., Ltd. in May 2015. It operates as a subsidiary under the umbrella of Guangdong HEC Technology Holding Co., Ltd.
Key people
Xinfa Tang
Non-Executive Chairman of the Board · since 2015
Qiang Zhang
Chief Financial Officer · since 2019
Yangui Chen
Executive Director · since 2014
Shuang Li
Deputy General Manager, Executive Director · since 2018
Qiaohong Zhu
Deputy General Manager, Executive Director · since 2017
Qiyun Peng
Joint Company Secretary · since 2018
Eddy Huang
Non-Executive Director · since 2019
Non-Executive Independent Director · since 2015
Dayao Zhao
Non-Executive Independent Director · since 2019
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||